Skip to content
← Back to this collection

PUBLICATIONS · 22981498

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Eur J Cancer
Publication date
2013 Jan
First author
Duvic M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Duvic M
      type
      Author
    2. name
      Dummer R
      type
      Author
    3. name
      Becker JC
      type
      Author
    4. name
      Poulalhon N
      type
      Author
    5. name
      Ortiz Romero P
      type
      Author
    6. name
      Grazia Bernengo M
      type
      Author
    7. name
      Lebbé C
      type
      Author
    8. name
      Assaf C
      type
      Author
    9. name
      Squier M
      type
      Author
    10. name
      Williams D
      type
      Author
    11. name
      Marshood M
      type
      Author
    12. name
      Tai F
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Duvic M
      type
      Author
    2. name
      Dummer R
      type
      Author
    3. name
      Becker JC
      type
      Author
    4. name
      Poulalhon N
      type
      Author
    5. name
      Ortiz Romero P
      type
      Author
    6. name
      Grazia Bernengo M
      type
      Author
    7. name
      Lebbé C
      type
      Author
    8. name
      Assaf C
      type
      Author
    9. name
      Squier M
      type
      Author
    10. name
      Williams D
      type
      Author
    11. name
      Marshood M
      type
      Author
    12. name
      Tai F
      type
      Author
    bibliography ids
    1. nci-bib-7c676a86edf90a192e66ba46
    book metadata
    content sha256
    6575a976596fb5fee3f95129b99d5812cc79dfc49ef9a07f7f39e2db3904bac1
    document type
    citation
    dois
    1. 10.1016/j.ejca.2012.08.017
    electronic publication date
    display
    2012 Sep 13
    precision
    day
    year
    2012
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:22981498
    immutable id
    pubmed:22981498@6575a976596fb5fee3f95129b99d5812cc79dfc49ef9a07f7f39e2db3904bac1
    journal
    abbreviation
    Eur J Cancer
    issn electronic
    1879-0852
    issn print
    0959-8049
    issue
    2
    name
    European journal of cancer (Oxford, England : 1990)
    nlm unique id
    9005373
    pages
    386-94
    volume
    49
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      22981498
      provenance
      batch id
      1e3045de9f47a5ccd566
      provider
      NCBI PubMed ESummary
      record sha256
      57b62fd41d79695d28b95e5d941a6c23513da17682eee80c79164cd44f6c7d1b
      response sha256
      0c42e87ee821aef9d804e2d77dfdba8876f375111db163986dd22ba43a3d6a52
      retrieved at
      2026-09-09T23:46:50.128287+00:00
      publication date
      display
      2013 Jan
      precision
      month
      year
      2013
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Multicenter Study
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/22981498/
      title
      Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

      Preserved source evidence · Not medical advice